Lipocine (NASDAQ:LPCN) Director Buys $252,150.00 in Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi acquired 123,000 shares of Lipocine stock in a transaction that occurred on Monday, April 6th. The stock was acquired at an average cost of $2.05 per share, with a total value of $252,150.00. Following the purchase, the director directly owned 163,797 shares of the company’s stock, valued at $335,783.85. This represents a 301.49% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Lipocine Stock Down 5.4%

NASDAQ LPCN traded down $0.11 during midday trading on Monday, hitting $1.94. 2,564,708 shares of the company traded hands, compared to its average volume of 470,773. Lipocine Inc. has a 52 week low of $1.81 and a 52 week high of $12.37. The company’s 50-day simple moving average is $8.10 and its 200-day simple moving average is $5.78.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The firm had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Investors Weigh In On Lipocine

Several institutional investors have recently added to or reduced their stakes in LPCN. Squadron Capital Management LLC acquired a new position in shares of Lipocine during the fourth quarter valued at about $4,256,000. Diadema Partners LP acquired a new stake in Lipocine in the 4th quarter worth approximately $2,095,000. Ikarian Capital LLC purchased a new stake in Lipocine during the 4th quarter worth approximately $1,602,000. Persistent Asset Partners Ltd purchased a new stake in Lipocine during the 4th quarter worth approximately $567,000. Finally, Boothbay Fund Management LLC acquired a new position in Lipocine during the 4th quarter valued at approximately $441,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

Analyst Upgrades and Downgrades

LPCN has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Lipocine from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Friday, March 27th. Finally, HC Wainwright restated a “neutral” rating on shares of Lipocine in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Lipocine currently has a consensus rating of “Hold” and an average target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.